Lucas Gonzalez Herrera González-Herrera

Prof. Dr. Lucas Gonzalez Herrera González-Herrera

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2012 in Breast Cancer Research
Verified
Journal Article
Open access
RNRosa Nadal
Rosa Nadal
AFAna Fernandez
Ana Fernandez
PSPedro Sanchez-Rovira
Pedro Sanchez-Rovira
MSMarta Salido
Marta Salido
MRMaría Rodríguez
María Rodríguez
MSMaría Jose Serrano
María Jose Serrano
Introduction: Increasing evidence supports the view that the detection of circulating tumor cells (CTCs) predicts outcomes of nonmetastatic breast cancer patients. CTCs differ genetically from the primary tumor and may contribute to variations in prognosis and response to therapy. As we start to understand more about the biology of CTCs, we can begin to address how best to treat this form of disease. Methods: Ninety-eight nonmetastatic breast cancer patients were included in this study. CTCs were isolated by immunomagnetic techniques using magnetic beads labelled with a multi-CK-specific antibody (CK3-11D5) and CTC detection through immunocytochemical methods. Estrogen receptor, progesterone receptor and epidermal growth factor receptor (EGFR) were evaluated by immunofluorescence experiments and HER2 and TOP2A by fluorescence in situ hybridization. We aimed to characterize this set of biomarkers in CTCs and correlate it with clinical-pathological characteristics. Results: Baseline detection rate was 46.9% ≥ 1 CTC/30 ml threshold. CTC-positive cells were more frequent in HER2-negative tumors (p = 0.046). In patients younger than 50 years old, HER2-amplified and G1-G2 tumors had a higher possibility of being nondetectable CTCs. Heterogeneous expression of hormonal receptors (HRs) in samples from the same patients was found. Discordances between HR expression, HER2 and TOP2A status in CTCs and their primary tumor were found in the sequential blood samples. Less that 35% of patients switched their CTC status after receiving chemotherapy. EGFR-positive CTCs were associated with Luminal tumors (p = 0.03). Conclusions: This is the largest exploratory CTC biomarker analysis in nonmetastatic BC patients. Our study suggests that CTC biomarkers profiles might be useful as a surrogate marker for therapeutic selection and monitoring since heterogeneity of the biomarker distribution in CTCs and the lack of correlation with the primary tumor biomarker status were found. Further exploration of the association between EGFR-positive CTCs and Luminal tumors is warranted.

1 October 2013 in Forensic Science International
Verified
Journal Article
Closed access
LGLucas Gonzalez Herrera González-Herrera
Lucas Gonzalez Herrera González-Herrera
AVAurora Valenzuela
Aurora Valenzuela
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
JLJose Antonio Lorente
Jose Antonio Lorente
EVEnrique Villanueva
Enrique Villanueva

8 March 2016 in Forensic Science, Medicine and Pathology
Verified
Journal Article
Closed access
PDF file
LGLucas Gonzalez Herrera González-Herrera
Lucas Gonzalez Herrera González-Herrera
AVAurora Valenzuela
Aurora Valenzuela
VRValentín Ramos
Valentín Ramos
ABAntonia Blázquez
Antonia Blázquez
EVEnrique Villanueva
Enrique Villanueva

1 September 2019 in Forensic Science International
Verified
Journal Article
Closed access
LGLucas Gonzalez Herrera González-Herrera
Lucas Gonzalez Herrera González-Herrera
AMAna Belén Márquez-Ruiz
Ana Belén Márquez-Ruiz
MSMaría Jose Serrano
María Jose Serrano
VRValentín Ramos
Valentín Ramos
JLJose Antonio Lorente
Jose Antonio Lorente
AVAurora Valenzuela
Aurora Valenzuela

20 January 2025 in Carcinogenesis
Verified
Journal Article
Open access
CMCarlos Muñoz-Bravo
Carlos Muñoz-Bravo
IMInés Marín-Burdallo
Inés Marín-Burdallo
LGLucas Gonzalez Herrera González-Herrera
Lucas Gonzalez Herrera González-Herrera
CTCarla González-Palacios Torres
Carla González-Palacios Torres
MLMacarena Lozano-Lorca
Macarena Lozano-Lorca
RORocío Olmedo-Requena
Rocío Olmedo-Requena
Several clinical studies have evaluated the relationship between copper on colorectal cancer (CRC), but the results are contradictory. This study aimed to conduct a systematic review and meta-analysis to investigate copper measured in two biological matrices (serum/plasma/blood and tissue) and dietary intake in CRC patients compared to healthy controls. We conducted a comprehensive and systematic search in PubMed, Scopus, Embase, and Web of Science. We included studies that reported copper levels in serum/plasma/blood, tissue, or from the diet, with an observational study design (cohort and case–control studies). Study quality was assessed with the Newcastle–Ottawa scale and potential causes of heterogeneity were evaluated. Standardized mean differences (SMD) with 95% confidence interval (CI) were pooled using random-effect models. Overall pooled odds ratio and 95% CI for the risk of CRC were calculated. Twenty-six studies (23 case–control and 3 cohort studies) with a total of 227 354 participants were included. Most of the studies presented low (50%) or moderate quality (42.3%). No differences in serum/plasma/blood copper levels (SMD = 0.23; 95% CI: −0.23, 0.70; I2 = 97.3%, 19 studies), tissue copper levels (SMD = −1.69; 95% CI: −3.41, 0.03; I2 = 85.6%, 2 studies), or copper/zinc ratio (SMD = 1.19; 95% CI: 0.54, 1.84; I2 = 95.3%, 6 studies) were found between CRC patients and healthy controls. Regarding dietary copper, CRC patients had a lower intake (SMD = −0.27; 95% CI: −0.51, −0.03; I2 = 0.0%, 2 studies). No differences were found in copper levels between CRC patients and healthy controls. However, evidence shows mostly low or moderate quality, and results were heterogeneous. More prospective studies with an adequate methodological approach are needed.

José Carlos Vera JiménezJosé Carlos Vera Jiménez
José Carlos Vera Jiménez
JLJose Antonio Lorente
Jose Antonio Lorente
LGLucas Gonzalez Herrera González-Herrera
Lucas Gonzalez Herrera González-Herrera
JÁJosé A. Álvarez
José A. Álvarez
Marta Ferreiro-GonzálezMarta Ferreiro-González
Marta Ferreiro-González
Jesus AyusoJesus Ayuso
Jesus Ayuso
Background: The physical intervention techniques (PITs) typically used by the police in troublesome situations are examined in terms of injuring potential depending on whether they target a body zone of high, medium or low vulnerability. Based on legal and forensic considerations, and principles of congruence, opportunity and proportionality, a need exists to favor opponent locking and arrest techniques targeting non-vulnerable zones to minimize the risk of severe damage. Methods: A search of the training manuals for the different kind of law of enforcement officers was carried out. Revision of injuries was available from electronic databases of academic o medical journals. Results: Three different locking and arrest PITs based on operational tactical procedures (OTP) that avoid zones of high or medium vulnerability are proposed. The new techniques use blocking, diverting and grabbing of the upper and lower limbs, followed by dislocation and locking of the same targets. Conclusions: The damaging potential of such PITs was assessed in terms of anatomical region and most were found to have a high risk of severe damage. The alternative PITs proposed here, which rely on OTP, improve in legal and forensic medical terms on existing choices and dramatically reduce the risk of injuring arrestees.